Dr. Leisha Daly, Janssen Ireland country director and president of the Irish Pharmaceutical Healthcare Association (IPHA) discusses her presidency and the conclusion of a four-year agreement between IPHA and the Irish government on the supply of medicine. She then highlights Janssen’s leadership in Ireland in terms of ‘open-innovation’ and ‘beyond-the-pill’ approaches, and her mission to make Janssen the most trusted company in Ireland.
Firstly, let us discuss your term as the President of the Irish Pharmaceutical Healthcare Association (IPHA), which comes to an end in September. What have been some of the key milestones?
We have expanded the basket of countries that Ireland references, from 9 to 15 ... increased the existing government rebate from 4 percent to 5.25 percent in the community and 5 percent in hospitals [and] the prices of biologics will reduce by 30 percent.
